{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:04:13Z","timestamp":1790143453083,"version":"4.0.1"},"reference-count":42,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Microorganisms"],"abstract":"<jats:p>Invasive fungal diseases (IFDs) represent an escalating global health threat, compounded by the rapid emergence of antifungal resistance (AFR). This review synthesizes the contemporary landscape of AFR from clinical and microbiological perspectives, providing actionable insights for clinical practitioners. We examine the epidemiology of critical pathogens, including Candidozyma auris, clonal Candida parapsilosis, azole-resistant Aspergillus fumigatus, and dissect the underlying molecular mechanisms, from genetic mutations in ERG11 and cyp51A to novel emerging epigenetic and adaptive strategies. We critically appraise the diagnostic gap between phenotypic testing and clinical urgency, highlighting the role of rapid molecular assays and next-generation sequencing. Finally, we evaluate evidence-based therapeutic strategies, including the integration of novel agents such as rezafungin, ibrexafungerp, olorofim, and fosmanogepix), while emphasizing the imperative of antifungal stewardship, infection prevention and control in mitigating resistance, and \u201cOne-Health\u201d interventions.<\/jats:p>","DOI":"10.3390\/microorganisms14030599","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T13:00:02Z","timestamp":1772802002000},"page":"599","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The Silent Pandemic: Antifungal Resistance and the Future of Invasive Fungal Disease Management"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1279-1738","authenticated-orcid":false,"given":"Ruchika","family":"Bagga","sequence":"first","affiliation":[{"name":"Department of Pathobiology and Laboratory Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON N6A 3K7, Canada"},{"name":"Department of Pathobiology and Laboratory Medicine, London Health Sciences Centre, London, ON N6A 5W9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7139-8134","authenticated-orcid":false,"given":"Kumudhavalli","family":"Kavanoor Sridhar","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine & Pathobiology, University of Toronto, Toronto, ON M5S 3K3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2022). WHO Fungal Priority Pathogens List to Guide Research, Development and Public Health Action, World Health Organization."},{"key":"ref_2","unstructured":"World Health Organization (2024). 2024 GLASS Data-Call for Antifungals, World Health Organization."},{"key":"ref_3","unstructured":"CDC (2024). Antimicrobial Resistance Threats in the United States, 2021\u20132022."},{"key":"ref_4","unstructured":"CDC (2026, February 08). Antimicrobial-Resistant Fungal Diseases Data Portal, Available online: https:\/\/www.cdc.gov\/fungal\/."},{"key":"ref_5","unstructured":"ECDC (2025). Surveillance of Antimicrobial Resistance in Europe, 2024 Data."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"ofaf747","DOI":"10.1093\/ofid\/ofaf747","article-title":"Antifungal Resistance Surveillance: Insights From National Mycology Reference Centers and Expert Mycology Laboratories","volume":"12","author":"Alanio","year":"2025","journal-title":"Open Forum Infect Dis."},{"key":"ref_7","unstructured":"ECDC (2024). Laboratory Survey on Candida auris Epidemiology and Laboratory Capacity."},{"key":"ref_8","first-page":"121","article-title":"Mechanisms of Candida biofilm drug resistance","volume":"77","author":"Taff","year":"2023","journal-title":"Annu. Rev. Microbiol."},{"key":"ref_9","unstructured":"Infection Control Today (2025). Unraveling a Candida auris Outbreak: Infection Control Challenges in a Burn ICU, Infection Control Today."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/clinchem\/hvae185","article-title":"Genetic and Phenotypic Intra-Clade Variation in Candida auris Isolated from Critically Ill Patients in a New York City Tertiary Care Center","volume":"71","author":"Smithgall","year":"2025","journal-title":"Clin. Chem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e70111","DOI":"10.1111\/myc.70111","article-title":"Inter-Hospital Spread of Fluconazole-Resistant C. parapsilosis in Northern Italy: Insights into Clonal Distribution, Resistance Mechanisms and Biofilm Production","volume":"68","author":"Palladini","year":"2025","journal-title":"Mycoses"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Batista, C.S.P., Rivera, A., Alvarez Albarran, M.T.A., Rubio, M., Belen-Figas, I., Lopez-Querol, C., Mir\u00f3, E., Navarro, F., and Sanchez-Reus, F. (2025). Community-Onset Fungemias: Epidemiology and Genomic Characterization at a Tertiary-Care Hospital in Barcelona, Spain. J. Fungi, 11.","DOI":"10.20944\/preprints202510.0749.v1"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s11046-025-00941-x","article-title":"Trends of Azole-Resistant Aspergillus fumigatus Susceptibility Over 12 Years from a German ECMM Excellence Center","volume":"190","author":"Verhasselt","year":"2025","journal-title":"Mycopathologia"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Kim, W.-B., Nho, D., Cho, S.-Y., Lee, D.-G., Park, C., and Lee, R. (2025). Geographically structured genotypes and resistance clustering in Aspergillus fumigatus. Eur. J. Clin. Microbiol. Infect. Dis.","DOI":"10.1007\/s10096-025-05390-4"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s44259-024-00055-2","article-title":"A one health roadmap towards understanding and mitigating emerging Fungal Antimicrobial Resistance: fAMR","volume":"2","author":"Fisher","year":"2024","journal-title":"npj Antimicrob. Resist."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1093\/jac\/dkx034","article-title":"Candida auris candidaemia in Indian ICUs: Analysis of risk factors","volume":"72","author":"Rudramurthy","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1469-0691.2001.tb00009.x","article-title":"Present status of the detection of antifungal resistance: The perspective from both sides of the ocean","volume":"7","year":"2001","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4668","DOI":"10.1038\/s41467-025-59898-6","article-title":"Targeting epigenetic regulators to overcome drug resistance in the emerging human fungal pathogen Candida auris","volume":"16","author":"Zhang","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Naik, S., Kashyap, D., Deep, J., Darwish, S., Cross, J., Mansoor, E., Garg, V.K., and Honnavar, P. (2024). Utilizing Next-Generation Sequencing: Advancements in the Diagnosis of Fungal Infections. Diagnostics, 14.","DOI":"10.3390\/diagnostics14151664"},{"key":"ref_20","unstructured":"(2025, December 22). Centre for Reviews and Dissemination. Salvage Combination Antifungal Therapy for Acute Invasive Aspergillosis May Improve Outcomes: A Systematic Review and Meta-Analysis. Database of Abstracts of Reviews of Effects (DARE), Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK292990\/."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.cmi.2021.06.005","article-title":"Detection of azole resistance in Aspergillus fumigatus complex isolates using MALDI-TOF mass spectrometry","volume":"28","author":"Zvezdanova","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Roberto, A.E.M., Xavier, D.E., Vidal, E.E., Vidal, C.F.L., Neves, R.P., and de Lima-Neto, R.G. (2020). Rapid Detection of Echinocandins Resistance by MALDI-TOF MS in Candida parapsilosis Complex. Microorganisms, 8.","DOI":"10.3390\/microorganisms8010109"},{"key":"ref_23","unstructured":"CLSI (2020). Performance Standards for Antifungal Susceptibility Testing of Yeasts, Clinical and Laboratory Standards Institute. [4th ed.]. CLSI Supplement M27."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1128\/AAC.48.9.3407-3411.2004","article-title":"Paradoxical effect of caspofungin: Reduced activity against Candida albicans at high drug concentrations","volume":"48","author":"Stevens","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_25","unstructured":"FDA (2026, February 08). The CDC & FDA Antibiotic Resistance Isolate Bank, Available online: https:\/\/wwwn.cdc.gov\/arisolatebank\/."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/QCO.0000000000001063","article-title":"Reassessment of the role of combination antifungal therapy in the current era","volume":"37","author":"Neoh","year":"2024","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_27","unstructured":"CDC (2025). Core Elements of Antifungal Stewardship."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/S1473-3099(25)00224-5","article-title":"Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: A single-arm, open-label, phase 2b study","volume":"25","author":"Maertens","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1186\/s13054-024-05117-5","article-title":"Rezafungin versus caspofungin for patients with candidaemia or invasive candidiasis in the intensive care unit: Pooled analyses of the ReSTORE and STRIVE randomised trials","volume":"28","author":"Girardis","year":"2024","journal-title":"Crit. Care"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"617.e1","DOI":"10.1016\/j.ajog.2025.07.040","article-title":"A phase 3, multicenter, randomized, placebo-controlled trial of monthly oral ibrexafungerp to reduce the incidence of recurrent vulvovaginal candidiasis","volume":"233","author":"Goje","year":"2025","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"101534","DOI":"10.1016\/j.mycmed.2025.101534","article-title":"Ibrexafungerp for the treatment of vulvovaginal candidiasis: A systematic review and meta-analysis of randomized placebo-controlled trials","volume":"35","author":"Kow","year":"2025","journal-title":"J. Mycol. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1093\/cid\/ciaf185","article-title":"Fosmanogepix for the Treatment of Invasive Mold Diseases Caused by Aspergillus Species and Rare Molds: A Phase 2, Open-Label Study (AEGIS)","volume":"81","author":"Hodges","year":"2025","journal-title":"Clin. Infect. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e01650-23","DOI":"10.1128\/aac.01650-23","article-title":"Phase 1 drug-drug interaction study to assess the effect of CYP3A4 inhibition and pan-CYP induction on the pharmacokinetics and safety of fosmanogepix in healthy participants","volume":"68","author":"Hodges","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"ofaf034","DOI":"10.1093\/ofid\/ofaf034","article-title":"Long-term Safety and Effectiveness of Rezafungin Treatment in Candidemia and Invasive Candidiasis: Results from an Early Access Program in Italy and Germany","volume":"12","author":"Trapani","year":"2025","journal-title":"Open Forum Infect. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1186\/s13054-024-05152-2","article-title":"Length of hospital and intensive care unit stay in patients with invasive candidiasis and\/or candidemia treated with rezafungin: A pooled analysis of two randomised controlled trials","volume":"28","author":"Bassetti","year":"2024","journal-title":"Crit. Care"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1093\/ofid\/ofy358","article-title":"Twenty Years of the SENTRY Antifungal Surveillance Program: Results for Candida Species From 1997\u20132016","volume":"6","author":"Pfaller","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1093\/jac\/dkaf384","article-title":"In vitro and clinical data demonstrate negligible risk of drug\u2013drug interactions with opelconazole, a novel inhaled antifungal agent","volume":"80","author":"Cass","year":"2025","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41541-025-01079-z","article-title":"Developing mRNA lipid nanoparticle vaccine effective for cryptococcosis in a murine model","volume":"10","author":"Li","year":"2025","journal-title":"npj Vaccines"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"100522","DOI":"10.1016\/j.xops.2024.100522","article-title":"Development and Clinical Evaluation of a CRISPR\/Cas12a-Based Nucleic Acid Detection Platform for the Diagnosis of Keratomycoses","volume":"4","author":"Deivarajan","year":"2024","journal-title":"Ophthalmol. Sci."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"8953","DOI":"10.1038\/s41598-023-35085-9","article-title":"Interpretable deep learning for diagnosis of fungal and acanthamoeba keratitis using in vivo confocal microscopy images","volume":"13","author":"Essalat","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1093\/cid\/cis021","article-title":"Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: A patient-level quantitative review of randomized trials","volume":"54","author":"Andes","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.cmi.2018.11.027","article-title":"Triazole resistance in Aspergillus fumigatus: Recent insights and challenges for patient management","volume":"25","author":"Lestrade","year":"2019","journal-title":"Clin. Microbiol. Infect."}],"container-title":["Microorganisms"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-2607\/14\/3\/599\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T13:08:19Z","timestamp":1772802499000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-2607\/14\/3\/599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":42,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["microorganisms14030599"],"URL":"https:\/\/doi.org\/10.3390\/microorganisms14030599","relation":{},"ISSN":["2076-2607"],"issn-type":[{"value":"2076-2607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,6]]}}}